Dr. Aileen Z. Novero, MD

Dr. Novero practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Novero's NPI, 1154641421, was assigned on June 9, 2010. Dr. Novero graduated from Ross University School of Medicine in 2007. Dr. Novero's California license number on file is A110230.

Dr. Novero's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Novero's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Novero is also affiliated with Long Beach Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Novero to 3 more hospitals, 2 group practices and clinics, 1 home health agency, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Novero practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Novero's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Novero is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Novero's licenses on file in 2 states: California and New York.

Dmand AI lists chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Novero treats.

CMS data shows 15,195 Medicare services from Dr. Novero across 23 procedure codes in 2024, for 258 Medicare patients. Medicare paid $143,601 for them.

CMS counts 258 Medicare patients who saw Dr. Novero in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Novero's median patient age at 70, with 69% women.

In 2024, Dr. Novero wrote 2,378 Medicare Part D claims for 301 patients. 64% of them were for generic drugs. CMS names the drug for 1,991 of them, across 54 drugs with 11 or more claims each, at $6,295,848 in total drug cost. In 2023, CMS named 1,229 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Novero for performance year 2024, reported as part of a group. Dr. Novero accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Novero as offering telehealth.

Dmand AI links 5 papers to Dr. Novero, published from 2013 to 2014. 2014 was the busiest year, with 2. Dr. Novero's most frequent co-authors are Tauseef F. Ahmed, MD, Negin Behazin, MD and Arundhati Das, MD.

Dmand AI links Dr. Novero to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell.

CMS Open Payments shows 560 general payments to Dr. Novero from 62 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Celgene Corporation paid the most, $1,154.

Dr. Novero graduated from Ross University School of Medicine in 2007.

Dr. Novero is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.